Screening for heart failure in patients with diabetes mellitus in tertiary care – A SwissDiab study
Authors' conclusion
The fact that most cases of HF were previously undiagnosed and treatment with SGLT2i could be improved highlights the need to increase awareness of HF among healthcare professionals treating patients with diabetes.
Study context
- Population
- Patients with DM in tertiary care enrolled in the Swiss Diabetes Registry at one study centre, screened for heart failure (HF) per European Society of Cardiology recommendations; 31.5% T1D, 59.7% T2D, 8.8% other formsscreened
- Participants
- 534 patients
- Exposure
- T1D vs T2D vs Other forms
- Outcome
- Prevalence of HF
Methodological detailssingle-centre, screening based on European Society of Cardiology recommendations
- Single-centre
- Screening based on European Society of Cardiology recommendations
Main finding
As reported in the abstract
HF prevalence
- HF prevalence overall
- 11.2%
- HFpEF among HF
- 56.7%
- HFmrEF among HF
- 11.7%
- HFrEF among HF
- 31.7%
Observational data: associations, not effects.
Further findings
HF diagnosis status
- Previously diagnosed
- 40.0%
- Diagnosed as a result of screening
- 60.0%
SGLT2i prescription in previously known HF (n=24)
- Prescribed SGLT2i
- 50.0%
- HFrEF patients prescribed SGLT2i
- 2 out of 3
Original publication
Screening for heart failure in patients with diabetes mellitus in tertiary care – A SwissDiab study. Diabetes Res Clin Pract. Published 7 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →